Pharma BD Deal Intelligence

Novartis AG / Aduro Biotech, Inc. (STING pathway program)

2015 · Co-Development · $750M · Terminated

Novartis and Aduro entered an up-to-$750M global cancer immunotherapy collaboration targeting the STING pathway. Aduro received $200M upfront plus equity investment with up to $500M+ in milestones plus royalties; the partners co-developed STING agonists with Novartis launching a new immuno-oncology research group. Novartis later terminated work on STING program (2019).

Key facts

• Announced Mar 29, 2015
• Closed Mar 29, 2015
• Deal value $750M
• Deal type Co-Development
• Therapeutic area Solid tumors (immuno-oncology)
• Indications Solid tumors (immuno-oncology)
• Key assets ADU-S100 / STING pathway agonists
• Mechanism Stimulator of Interferon Genes (STING) pathway agonist (small molecule)

← Browse all deals  ·  How we score deals